TScan Therapeutics (TCRX) Net Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly Net Margin came in at 2888.58% in Q2 2026, down 168728.0% year-over-year from N/an in Q2 2025, and up 1.05% quarter-over-quarter from 2919.14% in Q1 2026.
Powered by 
Analysis
TScan Therapeutics (TCRX) Net Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Net Margin for 7 consecutive years, with 2888.58% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Margin fell 168728.0% year-over-year to 2888.58% in Q2 2026; TTM through Jun 2026 was 1655.35%, a 29387.0% increase from a year earlier, with the FY2025 full-year figure at 1256.81%, up 323214.0% from the prior year.
- Net Margin was 2888.58% for Q2 2026 at TScan Therapeutics, up from 2919.14% in the prior quarter.
- Over five years, Net Margin peaked at 271.99% in Q4 2023 and troughed at 5906.9% in Q2 2024.
- A 5-year average of 1897.48% and a median of 1048.2% in 2025 frame the typical range for Net Margin.
- Across the five-year window, Net Margin slumped 514308 bps in 2024 and surged 470560 bps in 2025, its largest moves.
- Over 5 years, Net Margin stood at 604.94% in 2022, then surged by 55 bps to 271.99% in 2023, then slumped by 1820 bps to 5220.9% in 2024, then soared by 83 bps to 895.09% in 2025, then tumbled by 223 bps to 2888.58% in 2026.
- The last three Net Margin figures came in at 2888.58% (Q2 2026), 2919.14% (Q1 2026), and 895.09% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,036.33% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | TScan Therapeutics | 42.91 Mn | 42.91 Mn | - | -2,888.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,888.58% |
| Mar 31, 2026 | -2,919.14% |
| Dec 31, 2025 | -895.09% |
| Sep 30, 2025 | -1,422.14% |
| Jun 30, 2025 | -1,201.30% |
| Mar 31, 2025 | -1,571.95% |
| Dec 31, 2024 | -5,220.90% |
| Sep 30, 2024 | -2,849.09% |
| Jun 30, 2024 | -5,906.90% |
| Mar 31, 2024 | -5,325.44% |
| Dec 31, 2023 | -271.99% |
| Sep 30, 2023 | -591.64% |
| Jun 30, 2023 | -763.82% |
| Mar 31, 2023 | -331.66% |
| Dec 31, 2022 | -604.94% |
| Sep 30, 2022 | -483.05% |
| Jun 30, 2022 | -372.21% |
| Mar 31, 2022 | -534.79% |
| Dec 31, 2021 | -497.55% |
| Sep 30, 2021 | -656.67% |